<DOC>
	<DOC>NCT01165320</DOC>
	<brief_summary>The study estimates the safety, efficacy, and pharmacokinetics of caspofungin (MK-0991) in Japanese children and adolescents with documented Candida or Aspergillus infections.</brief_summary>
	<brief_title>A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Candidiasis, Invasive</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Japanese patients in whom a causative fungus is detected before treatment with the study drug or patients with strongly suspected deepseated fungal infection due to Candida species (spp.) or Aspergillus spp. Patients with mycoses other than ones due to Candida spp. or Aspergillus spp. Patients who will receive other systemic antifungal agents for the first time in screening period</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>